Skip to main content
. 2015 Jun 25;8(3):80–88. doi: 10.5539/gjhs.v8n3p80

Table 2.

Changes in the clinical parameters in the two protocols during the trial phase

Parameter Moxifloxacin Control group
Baseline 6 months Baseline 6 months
Clinical Atthacment Level (mean±SD) 4.92±0.5* 3.14±0.6** 4.93±0.4* 3.77±0.4**
Probing Depth (mean±SD) 4.27±0.4* 3.08±0.6** 4.34±0.5* 3.5±0.4**

SD: standard deviation;

*

Changes were detected among the two time evaluations (repeated-measures ANOVA p<0.001);

**

Changes were perceived between the treatments (t -test p<0.001).

HHS Vulnerability Disclosure